CD274 and neoplasm: Therefore, the PD-1/PD-L1 pathway became a critical immune checkpoint used by TME-tumor “collaboration” to suppress anti-tumor immunity, but at the same time, it turned into a feasible target for the development of pharmacological agents aimed to inhibit zthe PD-1/PD-L1 interaction and restore the anti-tumoral response of the T cells.